PHASE-II STUDY OF RECOMBINANT HUMAN INTERFERON-GAMMA FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA

被引:129
作者
KAPLAN, EH
ROSEN, ST
NORRIS, DB
ROENIGK, HH
SAKS, SR
BUNN, PA
机构
[1] NORTHWESTERN UNIV,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60611
[2] NORTHWESTERN UNIV,DEPT DERMATOL,CHICAGO,IL 60611
[3] LAKESIDE VET ADM MED CTR,CHICAGO,IL 60611
[4] UNIV COLORADO,CTR CANC,DEPT DERMATOL,DENVER,CO 80202
关键词
D O I
10.1093/jnci/82.3.208
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recombinant human interferon gamma (rIFN- γ) was used for the treatment of 16 patients with various stages of cutaneous T-cell lymphoma (CTCL). All patients had been previously treated with standard topical and/or systemic therapies, and some had received experimental treatment with retinoids, recombinant human interferon alfa-2a (rIFN-α2a), or radiolabeled monoclonal antibodies; most patients had an advanced stage of disease. Objective partial responses (PRs) were noted in five patients (31%) and lasted 3 months to greater than 32 months (median, 10 mo). One of these five patients had previously had disease progression after an initial PR with rIFN-α2a. Six other patients (38%) showed minor or mixed responses. The most common side effects of rIFN-γ included fever, weight loss, mild neutropenia, elevated lac-tate dehydrogenase, and elevated hepatic transaminases. Additionally, one episode of nephrotic syndrome and one cutaneous allergic reaction were noted. None of the toxic effects were life threatening, and all were reversible. These results suggest that rIFN-γhas efficacy in the treatment of CTCL refractory to rIFN-α2a. [J Natl Cancer Inst 82: 208-212, 1990]. © 1990 Oxford University Press.
引用
收藏
页码:208 / 212
页数:5
相关论文
共 24 条
[1]   PURIFIED HUMAN IMMUNE INTERFERON HAS MORE POTENT ANTICELLULAR ACTIVITY THAN FIBROBLAST OR LEUKOCYTE INTERFERON [J].
BLALOCK, JE ;
GEORGIADES, JA ;
LANGFORD, MP ;
JOHNSON, HM .
CELLULAR IMMUNOLOGY, 1980, 49 (02) :390-394
[2]   SEZARY SYNDROME - MALIGNANT PROLIFERATION OF HELPER T CELLS [J].
BRODER, S ;
EDELSON, RL ;
LUTZNER, MA ;
NELSON, DL ;
MACDERMOTT, RP ;
DURM, ME ;
GOLDMAN, CK ;
MEADE, BD ;
WALDMANN, TA .
JOURNAL OF CLINICAL INVESTIGATION, 1976, 58 (06) :1297-1306
[3]   RECOMBINANT LEUKOCYTE A-INTERFERON - AN ACTIVE AGENT IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS [J].
BUNN, PA ;
FOON, KA ;
IHDE, DC ;
LONGO, DL ;
EDDY, J ;
WINKLER, CF ;
VEACH, SR ;
ZEFFREN, J ;
SHERWIN, S ;
OLDHAM, R .
ANNALS OF INTERNAL MEDICINE, 1984, 101 (04) :484-487
[4]  
BUNN PA, 1986, CANCER, V57, P1689, DOI 10.1002/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO
[5]  
2-M
[6]  
BUNN PA, 1979, CANCER TREAT REP, V63, P725
[7]  
COVELLI A, 1987, P ASCO, V6
[8]   SYNERGISTIC ANTIVIRAL AND ANTIPROLIFERATIVE ACTIVITIES OF ESCHERICHIA-COLI-DERIVED HUMAN ALPHA-INTERFERON, BETA-INTERFERON, AND GAMMA-INTERFERON [J].
CZARNIECKI, CW ;
FENNIE, CW ;
POWERS, DB ;
ESTELL, DA .
JOURNAL OF VIROLOGY, 1984, 49 (02) :490-496
[10]  
EPSTEIN EH, 1972, MEDICINE, V15, P61